Arbutus Biopharma Corporation - Common Stock (ABUS)

Competitors to Arbutus Biopharma Corporation - Common Stock (ABUS)

Assembly Biosciences, Inc. 

Assembly Biosciences competes with Arbutus Biopharma in the hepatitis B market by developing a range of novel therapies aimed at eliminating the virus. While both companies are targeting similar therapeutic areas, Assembly's proprietary technology and advanced clinical trials provide it with a competitive edge in the race to bring effective treatments to market. However, Arbutus's focus on RNA-targeted therapies may offer unique solutions that differentiate its product offerings.

Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals, while primarily focused on thrombocytopenia, has some overlap with Arbutus Biopharma in niche drug markets, making them indirect competitors. Dova differentiates itself with its focus on hematological conditions and established therapeutic approaches. While both companies operate in the biopharmaceutical space, Dova's targeted therapies may give it an advantage in specific patient populations and treatment paradigms, limiting direct competition with Arbutus.

Gilead Sciences, Inc. 

Gilead Sciences, Inc. competes with Arbutus Biopharma primarily in the field of antiviral therapies, particularly for hepatitis B and other viral infections. Gilead's established portfolio of antiviral drugs and large market presence give it a competitive edge in terms of research capabilities and financial resources. In contrast, Arbutus focuses more on innovative RNA-targeted therapies and has a narrower pipeline, which may limit its reach and speed of drug development compared to Gilead.

Vir Biotechnology, Inc. 

Vir Biotechnology competes with Arbutus Biopharma mainly through its focus on immunotherapy and novel approaches to tackling viral infections, including hepatitis. Vir's collaboration with established pharmaceutical companies and its extensive research pipeline may give it a substantial advantage in resources and expertise, allowing for a quicker path to market. This competitive advantage can lead to superior product offerings, though both companies are engaged in the discovery and development of innovative treatments for viral diseases.